Targeting cytotoxic T lymphocyte-associated protein 4, PD-1, and PD-L1 using antibodies to block immunomodulatory checkpoints on tumor cells, immune cells, and endothelial cells is an effective NSCLC therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.